Alerta

DETECTION OF PATHOGENIC E. COLI STRAINS

Resumen de: WO2025233323A1

The invention relates to compositions of binding peptides, and individual binding peptides, capable of specific binding to either of two variants of OmpA occurring in pathogenic E. coli, and to methods employing these binding peptides for detection or isolation of pathogenic E. coli.

항-박테리아 단백질 복합체

Resumen de: MX2025009214A

The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.

一种马链球菌和马流产沙门菌二联融合抗原及应用

Resumen de: CN120924562A

本发明公开了一种马链球菌和马流产沙门菌二联融合抗原，其核苷酸序列如SEQ ID NO.1所示。本发明将马流产沙门菌的FljB与马链球菌的SeM、EAG、GAPDH部分抗原串联重组在一起，不仅可以同时预防马链球菌和马流产沙门菌2种不同的马传染病，还增强了小鼠的体液免疫应答水平，利用该融合抗原免疫可获得抵抗马链球菌和马流产沙门菌的攻毒保护效果，高于单独抗原蛋白的免疫和灭活全菌的免疫，这解决了以往灭活疫苗免疫效率低和免疫繁琐的问题，有利于降低免疫的成本。

抗细菌蛋白质复合物

Resumen de: MX2025009214A

The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.

PHAGE LYASE AND USE THEREOF

Resumen de: WO2025227308A1

A phage lyase with an amino acid sequence set forth in SEQ IN NO.2. The lyase can inhibit the growth of Staphylococcus, Escherichia, Klebsiella, and Salmonella bacteria, and can be used as an antibacterial substance in milk pollution control, belonging to the field of bioengineering. The phage lyase can be used for preparing an enzyme formulation alone or in a compounded manner to specifically inactivate bacteria such as Staphylococcus aureus, thereby providing an enzyme formulation source which is safe and free of toxic and side effects for controlling Staphylococcus aureus pollution in milk at present.

弱毒化サルモネラ・チフィムリウム（Ｓａｌｍｏｎｅｌｌａ ｔｙｐｈｉｍｕｒｉｕｍ）を使用する良性神経系腫瘍の処置

Resumen de: US2022125906A1

Compositions and methods for the treatment of benign nervous system tumors including schwannomas using attenuated Salmonella typhimurium and optionally one or more checkpoint inhibitors.

PD-L1 Salmonella mutant expressing anti-PD-L1 peptide and outer membrane vesicle thereof and pharmaceutical comprising the same

Resumen de: KR20230091594A

The present invention relates to a Salmonella mutant strain expressing anti-PD-L1 peptide, outer membrane vesicles thereof, and a pharmaceutical composition containing the same. The Salmonella mutant strain expresses the anti-PD-L1 peptide in an extracellular loop of an outer membrane protein A, and thus, the anti-PD-L1 peptide can be delivered stably and efficiently to the inside of the tumor due to the characteristics of Salmonella, and can exhibit an anti-tumor effect by inducing the activation of T cells through the formation of a bond with PD-1 of cancer cells, thereby using the Salmonella mutant strain or the membrane vesicles thereof for cancer treatment.

ANTI-BACTERIAL PROTEIN COMPLEX

Resumen de: MX2025009214A

The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.

Salmonella typhimurium aptamer lateral flow chromatography test strip based on photothermal effect of ferroferric oxide and colloidal gold composite nanomaterial as well as preparation method and application of salmonella typhimurium aptamer lateral flow chromatography test strip

Resumen de: CN120870552A

The invention discloses a salmonella typhimurium aptamer lateral flow chromatography test strip based on the photothermal effect of a ferroferric oxide and colloidal gold composite nanomaterial, a preparation method and application, and belongs to the technical field of lateral flow chromatography test strips. The preparation of the probe comprises the step of preparing a Fe3O4 (at) Au composite nano material; the preparation method comprises the following steps: under the protection of nitrogen, dissolving FeCl3. 6H2O and FeCl2. 4H2O in deionized water, adding ammonia water, stirring at room temperature, adding trisodium citrate, collecting by using a magnet, then adding into a boiling HAuCl4 solution, keeping boiling until the color of the solution becomes reddish brown, continuing heating, cooling, and collecting by using a magnet; the test strip provided by the invention can realize quantitative detection of salmonella typhimurium.

Application of combination of denosine and polymyxin in preparation of antibacterial drugs

Resumen de: CN120860179A

The invention belongs to the technical field of medicines, and particularly relates to application of pinosine and polymyxin in preparation of antibacterial drugs, and the antibacterial drugs aim at one or more of escherichia coli, salmonella and klebsiella pneumoniae. The antibacterial agent aims at bacteria which are resistant to polymyxin. The bacteria directed by the antibacterial agent are multi-drug-resistant gram-negative bacteria. A checkerboard method minimum inhibitory concentration test and an in-vitro time sterilization curve prove that the pinosine effectively recovers the sensitivity of bacteria to the polymyxin, and meanwhile, a staining experiment and fluorescent quantitative PCR prove that the pinosine can effectively recover the sensitivity of the bacteria to the polymyxin by destroying the completeness of a bacterial cell membrane and inhibiting the transcription expression of a polymyxin drug-resistant gene mcr-1. The antibacterial activity of the polymyxin on bacteria is effectively enhanced. The invention provides a novel application of densipine in enhancing the antibacterial activity of polymyxin antibiotics, and can solve the technical problems of low clinical drug resistance, low therapeutic index and the like of polymyxin.

Goose source Weissella cibaria F11 and application thereof

Resumen de: CN120866142A

The invention relates to the technical field of probiotic development and utilization, in particular to a goose source Weissella cibaria F11 and application thereof. The Weissella cibarius F11 is preserved in the China General Microbiological Culture Collection Center on July 11, 2025, and the preservation number is CGMCC NO.35211. The Weissella cibarius F11 has the characteristics of good acid resistance and cholate resistance, and can be used for preparing the acid-resistant and cholate-resistant strain. And the bacillus subtilis has a good inhibition effect on pathogenic bacteria such as escherichia coli, pseudomonas aeruginosa, staphylococcus aureus and salmonella typhimurium, and also has stable acid production capacity and good safety. The Weissella sinus F11 provided by the invention meets the probiotic characteristic standard, the antibiotic resistance spectrum of the Weissella sinus F11 meets the feed probiotic safety standard, the growth of goslings can be remarkably promoted, the death rate and diarrhea occurrence rate of the goslings can be remarkably reduced, and the weissella sinus F11 can be used for preparing feed probiotics. The development potential in the fields of preparation of bacteriostatic and antibacterial drugs, probiotics for poultry feed, feed additives, poultry feed and the like is huge.

Probe, kit and detection method for detecting salmonella

Resumen de: CN120866303A

The invention provides a probe, a kit and a detection method for detecting salmonella, and belongs to the technical field of pathogenic bacterium detection. The research provides an unmarked fluorescent biosensing platform for high-sensitivity detection of salmonella. A target sequence is introduced into a catalytic core sequence of Aurora DNAzyme, so that a signal probe E-Aurora is constructed. The E-Aurora can be combined with a substrate 4-methylumbelliferone phosphate disodium salt to generate a strong fluorescent compound 4-MU. When salmonella exists, PfAgo is activated and specifically cuts the E-Aurora probe, so that the structural integrity of E-Aurora is destroyed and the catalytic ability of E-Aurora is lost, and the generation of a fluorescence signal is hindered. The biosensor realizes ultra-high sensitivity detection of salmonella, the limit of detection (LOD) is as low as 1 CFU/mL, and an ideal recovery rate (80-120%) is obtained in actual sample detection. The detection method disclosed by the invention is simple to operate and wide in application range, and can be used for determining trace salmonella in food.

SYSTEMS, METHODS, AND COMPOSITIONS FOR THE DETECTION OF MICROBES

Resumen de: AU2024264505A1

Provided are non-naturally occurring systems, methods, and compositions for the detection of microbes. The disclosure relates to the detection of an antigen specific to a microbe, such as a foodborne, an environment-borne, and a bloodborne bacteria, using capture antibody and moiety, detector antibody and moiety, and a light-emitting particle.

HOST CELL PROTEIN DETECTION USING LATERAL FLOW DEVICES

Resumen de: US2025334572A1

Time sensitive biopharmaceutical processing updates can be implemented using lateral flow devices to test on-site during manufacturing. Lateral flow testing for an analyte such as, for example, impurities (e.g., host cell proteins), during manufacturing of a biopharmaceutical drug product is completed within twenty-five minutes of collecting a sample from the manufacturing line. That is, all sample preparation, such as adding reagent or diluting the sample, contacting the prepared sample to a lateral flow device, and detecting presence or absence of the analyte is completed within twenty-five minutes (e.g., 20 minutes, 18 minutes, 15 minutes) from collection such that processing adjustments during manufacturing can be implemented.

METHOD FOR DETECTING FOODBORNE PATHOGENS USING BACTERIOPHAGES

Resumen de: WO2025225874A1

The present invention relates to a method for detecting live foodborne pathogens using novel bacteriophages LEC1, LBC9, and LSE2. By using this method, Escherichia coli, Bacillus cereus, and Salmonella spp., which are live foodborne pathogens in food, can be rapidly and accurately detected at the same time, and thus the method can be effectively used for preventing food poisoning.

Composition or kit for detecting animal intestinal microorganism

Resumen de: KR20250155130A

본 발명은 서울특별시 서울기술연구원 2022년도 캠퍼스타운 기술매칭 지원사업(반려동물 장내미생물 자가검사키트)을 통해 개발된 기술이다. 본 발명은 동물의 장내미생물 검출용 조성물 또는 키트에 관한 것으로서, 본 발명의 조성물 또는 키트는 미생물 유래 독소에 특이적으로 결합할 수 있는 물질을 프로브로 포함함으로써, 시중에 널리 사용되는 코로나 자가검진 키트와 마찬가지로 소비자 스스로 반려동물의 장내미생물을 검사할 수 있도록 하고, 이에 따라 반려동물의 장내미생물 분석에 대한 소비자 접근성을 크게 향상시킬 수 있다.

HOST CELL PROTEIN DETECTION USING LATERAL FLOW DEVICES

Resumen de: WO2025224621A1

Time sensitive biopharmaceutical processing updates can be implemented using lateral flow devices to test on-site during manufacturing. Lateral flow testing for an analyte such as, for example, impurities (e.g., host cell proteins), during manufacturing of a biopharmaceutical drug product is completed within twenty-five minutes of collecting a sample from the manufacturing line. That is, all sample preparation, such as adding reagent or diluting the sample, contacting the prepared sample to a lateral flow device, and detecting presence or absence of the analyte is completed within twenty-five minutes (e.g., 20 minutes, 18 minutes, 15 minutes) from collection such that processing adjustments during manufacturing can be implemented.

MODIFIED MICROORGANISMS

Resumen de: WO2025224251A1

The present invention relates to a live attenuated Gram-negative bacterium comprising a modified hlyCABD operon, wherein the modified hlyCABD operon is split into a first segment and a second segment, the first segment being operably linked to a first independently controlled promoter, wherein the first independently controlled promoter is a strong constitutive promoter or a strong vacuole-induced promoter, and the second segment being operably linked to a second independently controlled promoter, wherein the second independently controlled promoter is a strong vacuole-induced promoter, and wherein the first segment comprises a heterologous polynucleotide encoding a lysin upstream of a hlyAs translocation sequence, wherein the heterologous polynucleotide encoding one or more cargo molecules replaces a hlyA gene, and wherein the second segment comprises hly genes involved in secretion.

VACUOLE ESCAPE

Resumen de: WO2025224268A1

The present invention relates to a live attenuated Gram-negative bacterium modified to enable enhanced vacuole escape. In particular, the invention relates to a live attenuated Gram-negative bacterium comprising a heterologous polynucleotide encoding a prokaryotic disulfide bond isomerase, or functional fragment thereof, wherein said heterologous polynucleotide encoding the prokaryotic disulfide bond isomerase is operably linked to a promoter, or a live attenuated Gram-negative bacterium comprising an endogenous prokaryotic disulfide bond isomerase, or functional fragment thereof, wherein the endogenous prokaryotic disulfide bond isomerase is upregulated compared to its basal level expression.

METHODS AND SYSTEMS FOR THE RAPID DETECTION OF LISTERIA USING INFECTIOUS AGENTS

Resumen de: EP4641200A2

Disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.

- Recombinant Microbials Expressing Strep-tag and Tumor Imaging Aduvant Comprising the Microbials

Resumen de: KR20240012662A

The present invention relates to a genetic construct characterized in that the anti-sigma factor flgM gene and the gene encoding strep-tag are linked to encode a fusion protein of flgM and strep-tag so that a strep-tag may be expressed on the surface of an anticancer strain that may be targeted to a tumor site and stimulate immune activity, and an anticancer adjuvant and a tumor imaging aid which is transformed thereby and exhibits anticancer activity itself and may be usefully used for the diagnosis and treatment of tumor cells together with an anticancer substance or contrast agent labeled with a substance which specifically reacts with the strep-tag.

BACTERIOPHAGES AND USE THEREOF FOR THE TREATMENT OR PREVENTION OF INFECTION CAUSED BY SALMONELLA GALLINARUM

Resumen de: WO2024137831A2

A composition of bacteriophages comprising at least one phage selected from TTS1, TTS2, TTS3, TTS4, TTS5, and TTS6, wherein the phages are optionally encapsulated; and a method for preventing or treating an infection caused by Salmonella Gallinarum by administering to a subject a therapeutically effective amount of the composition.

Salmonella enterica ultra-fast detection kit based on whole-process nucleic acid detection chip and detection method of salmonella enterica ultra-fast detection kit

Resumen de: CN120843705A

The invention discloses a salmonella enterica ultra-rapid detection kit based on a whole-process nucleic acid detection chip and a detection method thereof. The kit comprises a rapid hot start DNA polymerase, a PCR reaction mixed solution, a positive reference substance and a negative reference substance, the kit also comprises the following primers which take the salmonella enterica V3-V4 region as a target sequence and are designed by a PCR fluorescent probe method based on a whole-process nucleic acid detection chip technical platform: an upstream primer F, a downstream primer R and a detection probe P, and the nucleotide sequences of the three primers are shown as SEQ ID NO. 1-3. According to the detection kit disclosed by the invention, a V3-V4 target sequence can be rapidly detected on the micro-fluidic chip within more than ten minutes, so that the accuracy and the specificity of detecting the salmonella enterica gene are ensured; the invention provides the salmonella enterica gene detection kit which is more comprehensive in detection effect, high in specificity, good in sensitivity, low in omission ratio, convenient, simple and easy to operate.

Knowledge graph and deep learning fused food microbial pollution rapid detection method

Resumen de: CN120850205A

The invention relates to the technical field of food safety, and discloses a food microbial contamination rapid detection method fusing a knowledge graph and deep learning, and the method comprises a data collection module, a knowledge graph engine, a deep learning calculation unit, a dynamic optimization module, a visual interaction terminal and a traceability management platform. A micro-fluidic chip and impedance sensing combined technology is adopted, the traditional long-time detection period is shortened, the real-time monitoring requirement of cold-chain logistics is met, a spectrum-bioelectricity-microscopic image three-mode space-time alignment model is created for the first time, dimension gaps are eliminated through feature space mapping, the recognition accuracy of complex matrix pollution is improved, and the real-time monitoring requirement of the cold-chain logistics is met. By constructing a rule engine driven by an industry knowledge graph, dynamic model updating is achieved through an incremental learning module, the detection rate of novel salmonella variants is increased, and the problem of the omission ratio of new pathogens is solved.

一种用于防治多种致病性肠杆菌感染的融合蛋白及应用

Nº publicación: CN120842432A 28/10/2025

Solicitante:

南京澄实生物医药科技有限公司

Resumen de: CN120842432A

本发明涉及一种应对多种致病性肠杆菌感染防治的融合蛋白、免疫原性组合物、重组简并疫苗，以及分子架构设计和应用等。本发明筛选到3种细胞免疫抗原Tuf、DnaK、fusA，构建的3种抗原的融合蛋白分子可显著抑制多种肠杆菌感染引起的组织病变，具有良好的免疫原性，起到有效防治和免疫保护作用，广谱且高效地预防多种致病性肠杆菌感染，具有广阔的工业应用前景。